The possible existence of a Gut-Bone axis suggested by studies of genetically manipulated mouse models?

Current Pharmaceutical Design

Volumn 17, Issue 16, 2011, Pages 1552-1555

  Chen, Duan ^a   Zhao, Chun Mei ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Bone; CCK2 receptor; Gastric acid; Histidine decarboxylase; Lrp5; Serotonin

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; GASTRIN; HISTAMINE H2 RECEPTOR; HISTIDINE DECARBOXYLASE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; PROTON PUMP INHIBITOR; SEROTONIN;

ARTICLE; BLOOD; BONE; BONE MASS; DUODENUM; HUMAN; INTESTINE; KNOCKOUT MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PH;

ANIMALS; BONE AND BONES; GASTROINTESTINAL TRACT; MICE; MODELS, ANIMAL; SEROTONIN;

EID: 79959989472     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796196972     Document Type: Article

References (37)

1. Bussabarger RS, Freeman S, Ivy AC. The experimental productionof severe homogenous osteoporosis by gastrectomy in puppies. AmJ Physiol 1938; 121: 137-48.
2. Tovey FI, Hall ML, Ell PJ, Hobsley M. A review of postgastrectomybone disease. J Gastroenterol Hepatol 1992; 7: 639-45.
3. Mühlbauer RC, Schenk RK, Chen D, Lehto-Axtelius D, Ha °kansonR. Morphometric analysis of gastrectomy-evoked osteopenia. CalcifTissue Int 1998; 62: 323-6.
4. Lehto-Axtelius D, Chen D, Surve VV, Håkanson R. Postgastrectomyosteopenia in the rat: bone structure is preserved by retaining10%-30% of the oxyntic gland area. Scand J Gastroenterol 2002; 37: 437-43.
5. Heiskanen JT, Kröger H, Pääkkönen M, Parviainen MT, Lamberg-Allardt C, Alhava E. Bone mineral metabolism after total gastrectomy. Bone 2001; 28: 123-7.
6. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys 2010; 503: 11-9.
7. Nikolopoulos D, Theocharis S, Kouraklis G. Ghrelin, another factoraffecting bone metabolism. Med Sci Monit 2010; 16: 147-62.
8. Wong IP, Baldock PA, Herzog H. Gastrointestinal peptides andbone health. Curr Opin Endocrinol Diabetes Obes 2010; 17: 44-50.
9. Schinke T, Schilling AF, Baranowsky A, et al. Impaired gastricacidification negatively affects calcium homeostasis and bonemass. Nat Med 2009; 15: 674-81.
10. Boyce BF. Stomaching calcium for bone health. Nat Med 2009; 15:610-2.
11. Ferron M, Karsenty G. The gutsy side of bone. Cell Metab 2009;10: 7-8.
12. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibitinggastric acid production does not affect intestinal calcium absorptionin young, healthy individuals: a randomized, crossover, controlledclinical trial. J Bone Miner Res 2010; 25: 2205-11.
13. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitoruse is not associated with osteoporosis or accelerated bone mineraldensity loss. Gastroenterology 2010; 138: 896-904.
14. Cohen MM. The new bone biology: pathologic, molecular, andclinical correlates. Am J Med Genet A 2006; 140: 2646-706.
15. Banco R, Seifert MF, Marks SC, McGuire JL. Rickets and osteopetrosis:the osteosclerotic (oc) mouse. Clin Orthop Relat Res 1985; 201: 238-46.
16. Soriano P, Montgomery C, Geske R. Bradley A. Targeted disruptionof the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
17. Li YP, Chen W, Liang Y, Li E, Stashenko P. Atp6i-deficient miceexhibit severe osteopetrosis due to loss of osteoclast-mediated extracellularacidification. Nat Genet 1999; 23: 447-51.
18. Langhans N, Rindi G, Chiu M, et al. Abnormal gastric histologyand decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 1997; 112: 280-6.
19. Chen D, Zhao CM., Al-Haider W, Håkanson R, Rehfeld JF, Kopin AS. Differentiation of gastric ECL cells is altered in CCK2 receptor-deficient mice. Gastroenterology 2002; 123: 577-85.
20. Furutani K, Aihara T, Nakamura E, et al. Crucial role of histaminefor regulation of gastric acid secretion ascertained by histidine decarboxylase-knockout mice. J Pharmacol Exp Ther 2003; 307: 331-8.
21. Fitzpatrick LA, Buzas E, Gagne TJ, et al. Targeted deletion ofhistidine decarboxylase gene in mice increases bone formation andprotects against ovariectomy-induced bone loss. Proc Natl AcadSci USA 2003; 100: 6027-32.
22. Persson P, Håkanson R, Axelson J, Sundler F. Gastrin releases ablood calcium-lowering peptide from the acid-producing part of therat stomach. Proc Natl Acad Sci USA 1989; 86: 2834-8.
23. Chen D, Aihara T, Zhao CM, Håkanson R, Okabe S. Differentiation of the gastric mucosa. I. Role of histamine in controlof function and integrity of oxyntic mucosa: understanding gastricphysiology through disruption of targeted genes. Am J PhysiolGastrointest Liver Physiol 2006; 291: 539-44.
24. Chen D, Zhao CM. Genetically engineered mice: a new paradigmto study gastric physiology. Curr Opin Gastroenterol 2007; 23:602-6.
25. Chen D, Zhao CM. Complexity of gastric acid secretion revealedby targeted gene disruption in mice. Curr Pharm Des 2010; 16:1235-40.
26. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decreasein osteoblast proliferation, osteopenia, and persistent embryoniceye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002; 157: 303-14.
27. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation byinhibiting serotonin synthesis in the duodenum. Cell 2008; 135:825-37.
28. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling indifferentiated osteoblasts controls osteoclast differentiation. DevCell 2005; 8: 751-64.
29. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5(LRP5) affects bone accrual and eye development. Cell 2001; 107:513-23.
30. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDLreceptor-related protein 5 gene results in the autosomal dominanthigh-bone-mass trait. Am J Hum Genet 2002; 70: 11-9.
31. Boyden LM, Mao J, Belsky J, et al. High bone density due to amutation in LDL-receptor-related protein 5. N Engl J Med 2002;346: 1513-21.
32. Yadav VK, Ducy P. Lrp5 and bone formation: A serotonindependentpathway. Ann N Y Acad Sci 2010; 1192: 103-9.
33. Long F. When the gut talks to bone. Cell 2008; 135: 795-6.
34. Bliziotes M. Update in serotonin and bone. J Clin Endocrinol Metab 2010; 95: 4124-32.
35. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibitionof gut-derived serotonin synthesis is a potential bone anabolictreatment for osteoporosis. Nat Med 2010; 16: 308-12.
36. Rosen CJ. Serotonin rising--the bone, brain, bowel connection. NEngl J Med 2009; 360: 957-9.
37. Anderson GM, Cook EH Jr, Blakely RD. Serotonin rising. N Engl J Med 2009; 360: 2580; author reply 2581-2.